I

    Immix Biopharma Inc (IMMX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.03
    +0.09 (+0.65%)

    Market Cap: $992.39M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    44%(7/16)
    Avg Surprise
    -13.56%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.19
    Range$-0.21 - $-0.17
    6 analysts
    EPS Revisions
    1
    0
    7d
    2
    1
    30d
    EPS Estimate Drift
    90d ago$-0.20-6.1%
    60d ago$-0.17+8.7%
    30d ago$-0.17+10.4%
    7d ago$-0.18+8.3%
    Current$-0.19
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Dec 31, 2026
    EPS Consensus$-0.17
    Range$-0.43 - $0.06
    8 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.17---
    Sep 26EST
    		-$-0.19---
    Jun 26
    		$-0.18$-0.17-5.88%Miss+18.2%
    Mar 26
    		$-0.18$-0.21+14.29%Beat-20.0%
    Dec 25
    		$-0.28$-0.15-86.67%Miss-12.0%
    Sep 25
    		$-0.24$-0.19-26.32%Miss+0.0%
    Jun 25
    		$-0.22$-0.16-37.50%Miss-46.7%
    Mar 25
    		$-0.15$-0.23+34.78%Beat+31.8%
    Dec 24
    		$-0.25$-0.25+0.00%Beat-8.7%
    Sep 24
    		$-0.24$-0.16-50.00%Miss-4.3%
    Jun 24
    		$-0.15$-0.21+28.57%Beat+37.5%
    Mar 24
    		$-0.22$-0.23+4.35%Beat-22.2%
    Dec 23
    		$-0.23$-0.23+0.00%Beat+14.8%
    Sep 23
    		$-0.23$-0.23+0.00%Beat-108.7%
    Jun 23
    		$-0.24$-0.17-41.18%Miss-118.2%
    Mar 23
    		$-0.18$-0.14-28.57%Miss-80.0%
    Dec 22
    		$-0.27$-0.22-22.73%Miss+91.5%
    Sep 22
    		$-0.11$-0.11-0.18%Miss-451.0%
    Jun 22
    		$-0.11N/AN/ABeat+31.3%
    Mar 22
    		$-0.10N/AN/ABeat+44.9%
    Dec 21
    		$-3.16N/AN/ABeat-1641.0%
    Sep 21
    		$-0.02$0.00N/AMiss+42.0%
    Jun 21
    		$-0.16$0.00N/AMiss-306.1%
    Mar 21
    		$-0.18$0.00N/AMiss-360.7%
    Dec 20
    		$-0.18$0.00N/AMiss-
    Jun 20
    		$-0.03$0.00N/AMiss-
    Mar 20
    		$-0.04$0.00N/AMiss-
    Dec 19
    		$-0.04$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-15.94EV/EBITDA-0.37x
    Price/FCF-22.89xFCF Yield-4.37%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-34.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio25.13xQuick Ratio25.13x
    Trading Statistics
    Beta0.11Avg Volume1.58M
    52-Week High$15.1052-Week Low$1.94

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.63
    SMA 20$12.06
    SMA 50$10.69
    SMA 200$8.31
    EMA 10$13.44
    EMA 20$12.43
    EMA 50$11.04
    EMA 200$8.43

    MACD

    Line: 1.20Signal: 1.00Hist: 0.20

    ADX

    ADX: 37.2+DI: 32.6-DI: 11.1

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down20.0
    PSAR$15.10

    Bollinger Bands

    Upper Band$15.63
    Lower Band$8.48
    %B Position5928%(Upper)
    Band Width0.78

    RSI (14-Day)

    Neutral
    69.6

    Momentum Oscillators

    Stoch %K80.2
    Stoch %D82.6
    Williams %R-22.6
    ROC (10d)23.7%
    Momentum2.69
    CCI (20d)82.3
    MFI (14d)65.4

    Volatility Measures

    ATR (14d)$0.82(5.8%)
    StdDev (20d)1.79
    Hist Vol78.9%(High)

    Volume Flow

    VWAP$13.90
    OBV47.7M
    AD Line11.2M
    CMF (20d)0.438

    Volume Metrics

    Avg Vol (20d)1.6M
    Vol Ratio0.8x
    VWMA (20d)$12.21

    Pivot Points

    R3$14.56
    R2$14.37
    R1$14.15
    Pivot Point$13.96
    S1$13.74
    S2$13.55
    S3$13.33

    Advanced Oscillators

    TSI39.36
    Ultimate Osc65.0
    KST395.41

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$96,290$0$0$0$4,784$0
    Cost of Revenue$0$0$90,631$0$0$0N/A$0$0$0$3,076$0
    Gross Profit$0$0$-90,631$0$0$0$48,145$0$0$0$1,708$0
    Operating Expenses$12.46M$10.80M$10.89M$7.66M$6.72M$4.68M$4.99M$7.39M$4.70M$5.59M$5.38M$4.52M
    R&D$5.33M$5.98M$5.73M$4.58M$3.97M$1.98M$1.37M$4.45M$2.22M$3.25M$3.10M$2.11M
    SG&A$7.12M$4.82M$5.17M$3.08M$2.75M$2.71M$3.61M$2.95M$2.48M$2.34M$2.28M$2.42M
    Operating Income$-12,456,343$-10,803,855$-10,893,276$-7,662,509$-6,717,705$-4,682,925$-4,987,120$-7,394,931$-4,702,496$-5,590,133$-5,375,852$-4,523,796
    Interest Income$913,663$717,168$216,712$84,539$104,056$150,219$185,851$256,680$306,915$267,908$228,575$186,691
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-11,542,680$-10,086,687$-10,676,564$-7,577,970$-6,613,649$-4,532,706$-4,801,269$-7,138,251$-4,395,581$-5,322,225$-5,147,277$-4,337,105
    Income Tax Expense$14,322$0$11,266$7,722$8,914$9,822$10,785$11,144$10,269$8,839$8,089$6,807
    Net Income$-11,557,002$-10,086,687$-10,687,830$-7,585,692$-6,622,563$-4,542,528$-4,812,054$-7,149,395$-4,405,850$-5,331,064$-5,155,366$-4,343,912
    EBITDA$-12,325,459$-10,673,089$-10,802,645$-7,527,654$-6,637,870$-4,623,745$-4,945,783$-7,369,025$-4,678,201$-5,566,283$-5,372,776$-4,522,415
    EBIT$-12,456,343$-10,803,855$-10,893,276$-7,662,509$-6,717,705$-4,682,925$-4,987,120$-7,394,931$-4,702,496$-5,590,133$-5,375,852$-4,523,796
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IMMX

    News

    Tocqueville Asset Management L.P. Buys New Position in Immix Biopharma, Inc. $IMMX

    Tocqueville Asset Management L.P. has acquired a new position in Immix Biopharma, Inc. (NASDAQ:IMMX), purchasing 88,550 shares valued at approximately $913,000, giving them a 0.16% stake. Other institutional investors have also increased their holdings. Analysts currently rate Immix Biopharma as a "Moderate Buy" with a consensus price target of $21.29, despite the company recently reporting a quarterly loss worse than estimates.

    MarketBeat•8/21/26•
    Somewhat-Bullish

    Blue Owl Capital Holdings LP Makes New $4.51 Million Investment in Immix Biopharma, Inc. $IMMX

    Blue Owl Capital Holdings LP has initiated a new investment in Immix Biopharma, Inc. (NASDAQ:IMMX), acquiring 437,552 shares valued at approximately $4.51 million. This makes Immix Biopharma the 24th largest position in Blue Owl's portfolio, representing about 0.7% of its total holdings. The article also notes recent adjustments by other institutional investors and provides an overview of analyst ratings and the company's financial performance.

    MarketBeat•8/21/26•
    Somewhat-Bullish

    Immix Biopharma (NASDAQ:IMMX) Sets New 12-Month High - Still a Buy?

    Immix Biopharma (NASDAQ:IMMX) recently hit a new 52-week high of $12.76, closing at $11.81. Analysts maintain a "Moderate Buy" consensus with a target price of $21.29, despite the company reporting a quarterly loss of $0.18 per share, slightly missing estimates. Institutional investors hold 11.26% of the company, which is focused on developing immuno-oncology therapies targeting myeloid checkpoints.

    MarketBeat•8/19/26•
    Somewhat-Bullish

    Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5% - Here's Why

    Immix Biopharma (NASDAQ: IMMX) shares dropped 4.5% to $10.43 on Friday, with trading volume significantly below average. This decline followed the company missing its latest quarterly earnings estimate, reporting a loss of $0.18 per share against an expected $0.17 loss. Despite the recent dip, analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and a $21.29 price target, and institutional ownership stands at 11.26%, including a new significant position from BlackRock Inc.

    MarketBeat•8/14/26•
    Somewhat-Bearish

    Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management

    Eventide Asset Management, LLC, through its Eventide Healthcare & Life Sciences Fund, has reported a beneficial ownership of 3,891,019 shares of Immix Biopharma (IMMX) common stock, representing a 5.6% stake. This Schedule 13G filing indicates that Eventide holds sole voting and dispositive power over these shares, with Finny Kuruvilla, M.D., Ph.D. and Robin C. John reporting shared voting and dispositive power over the same amount. The three parties have agreed to act as joint reporting persons for this ownership, as of June 30, 2026.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About IMMX

    Does IMMX pay dividends?
    Immix Biopharma Inc (IMMX) does not currently pay a regular dividend.
    What is IMMX's market cap?
    Immix Biopharma Inc (IMMX) has a market capitalization of $992.39M with a current stock price of $14.03.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In